ArticleJAMA cardiology2020
Trends in Readmission and Mortality Rates Following Heart Failure Hospitalization in the Veterans Affairs Health Care System From 2007 to 2017.
Article in JAMA cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- The Effect of Recurrent Heart Failure Hospitalizations on the Risk of Cardiovascular and all-Cause Mortality: a Systematic Review and Meta-Analysis.Current cardiology reports · 2024Pooled it
- DASH-HF Study: A Pragmatic Quality Improvement Randomized Implementation Trial for Patients With Heart Failure With Reduced Ejection Fraction.Circulation. Heart failure · 2023Trial
- Investigating the effect of multimedia education in combination with teach-back method on quality of life and cardiac anxiety in patients with heart failure: a randomized clinical trial.BMC cardiovascular disorders · 2021Trial
- Temporal Trends and Predictors of Mortality in Heart Failure with Reduced Ejection Fraction: The Role of Renal Function and Left Ventricular Improvement.Journal of clinical medicine · 2026Article
- Clinical effectiveness of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: nationwide cohort study (REFINE-HFpEF).BMJ medicine · 2026Article
- External Exposome Factors and Adverse Heart Failure Outcomes in the OneFlorida+ Network: Retrospective Cohort Study.JMIR formative research · 2025Article
- Neighborhood Deprivation and Racial Disparities in Heart Failure Outcomes: A Counterfactual Approach.JACC. Advances · 2025Article
- Frequency of hyperkalemia during optimization of guideline-directed medical therapy in ambulatory patients with HFrEF.Frontiers in cardiovascular medicine · 2025Article
- Predictors and Trends of 30-day Readmissions in Patients With Acute Decompensated Heart Failure With Preserved Ejection Fraction: Insight From the National Readmission Database.International journal of heart failure · 2025Article
- Article
- Management and outcomes of heart failure hospitalization among older adults in the United States and Japan.ESC heart failure · 2024Article
- Treatment Patterns, Outcomes, and Persistence to Newly Started Heart Failure Medications in Patients with Worsening Heart Failure: A Cohort Study from the United States and Germany.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Article
- Initiation and continuation of pharmacological therapies in patients hospitalized for heart failure in Japan.Scientific reports · 2024Article
- Article
- Benchmarking System Monitoring on Quality Improvement in Percutaneous Coronary Intervention: A Nationwide Registry in Japan.JACC. Asia · 2024Article
- Temporal Trends in Heart Failure Management and Outcomes: Insights From a Japanese Multicenter Registry of Tertiary Care Centers.Journal of the American Heart Association · 2023Article
- Prognostic role of renal replacement therapy among hospitalized patients with heart failure in the Brazilian national public health system.Frontiers in cardiovascular medicine · 2023Article
- Article
- New Strategies to Prevent Rehospitalizations for Heart Failure.Current treatment options in cardiovascular medicine · 2022Review
- Trends for Readmission and Mortality After Heart Failure Hospitalisation in Malaysia, 2007 to 2016.Global heart · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Importance: The Centers for Medicare & Medicaid Services and the Veterans Affairs Health Care System provide incentives for hospitals to reduce 30-day readmission and mortality rates. In contrast with the large body of evidence describing readmission and mortality in the Medicare system, it is unclear how heart failure readmission and mortality rates have changed during this period in the Veterans Affairs Health Care System. Objectives: To evaluate trends in readmission and mortality after heart failure admission in the Veterans Affairs Health Care System, which had no financial penalties, in a decade involving focus on heart failure readmission reduction (2007-2017). Design, Setting, and Participants: This cohort study used data from all Veterans Affairs-paid heart failure admissions from January 2007 to September 2017. All Veterans Affairs-paid hospital admissions to Veterans Affairs and non-Veterans Affairs facilities for a primary diagnosis of heart failure were included, when the admission was paid for by the Veterans Affairs. Data analyses were conducted from October 2018 to March 2020. Exposures: Admission for a primary diagnosis of heart failure at discharge. Main Outcomes and Measures: Thirty-day all-cause readmission and mortality rates. Results: A total of 164 566 patients with 304 374 hospital admissions were included. Among the 304 374 hospital admissions between 2007 and 2017, 298 260 (98.0%) were for male patients, and 195 205 (64.4%) were for white patients. The mean (SD) age was 70.8 (11.5) years. The adjusted odds ratio of 30-day readmission declined throughout the study period to 0.85 (95% CI, 0.83-0.88) in 2015 to 2017 compared with 2007 to 2008. The adjusted odds ratio of 30-day mortality remained stable, with an adjusted odds ratio of 1.01 (95% CI, 0.96-1.06) in 2015 to 2017 compared with 2007 to 2008. Stratification by left ventricular ejection fraction showed similar readmission reduction trends and no significant change in mortality, regardless of strata. Conclusions and Relevance: In this analysis of an integrated health care system that provided guidance and nonfinancial incentives for reducing readmissions, such as public reporting of readmission rates, risk-adjusted 30-day readmission declined despite inclusion of clinical variables in risk adjustment, but mortality did not decline. Future investigations should focus on evaluating the effectiveness of specific approaches to readmission reduction to inform efficient and effective application in individual health systems, hospitals, and practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.